These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30367010)

  • 1. Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
    Li J; Li T; Li S; Xie L; Yang YL; Lin Q; Kadoch O; Li H; Hou S; Xu Z
    J Investig Med; 2019 Feb; 67(2):338-345. PubMed ID: 30367010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
    J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.
    Shimizu Y; Dobashi K; Imai H; Sunaga N; Ono A; Sano T; Hikino T; Shimizu K; Tanaka S; Ishizuka T; Utsugi M; Mori M
    Int J Immunopathol Pharmacol; 2009; 22(1):43-51. PubMed ID: 19309551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
    Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
    Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
    Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
    Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
    Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
    Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment.
    Karatkevich D; Losmanova T; Zens P; Deng H; Dubey C; Zhang T; Casty C; Gao Y; Neppl C; Berezowska S; Wang W; Peng RW; Schmid RA; Dorn P; Marti TM
    Sci Rep; 2024 Aug; 14(1):18206. PubMed ID: 39107509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
    Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 20. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.